FDA clears Editas to test gene-editing drug in humans

The study, which Editas said will involve 10 to 20 patients, will be the second company-sponsored clinical trial in the U.S. of a drug based on CRISPR/Cas9 technology.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.